US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia

NCT03118466 ·Status: COMPLETED ·Phase: PHASE2

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

NCT05776134 ·Status: AVAILABLE

Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia

NCT02674763 ·Status: COMPLETED ·Phase: PHASE1

Biomarkers for Personalized Early Assessment of Response During Salvage Chemotherapy in People With Relapsed or Refractory Acute Myeloid Leukemia (PEARL15)

NCT02527447 ·Status: COMPLETED

A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

NCT01564784 ·Status: COMPLETED ·Phase: PHASE3

Epigenetic Reprogramming in Relapse AML

NCT02412475 ·Status: TERMINATED ·Phase: PHASE1

Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML

NCT01849276 ·Status: TERMINATED ·Phase: PHASE1

Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT01550185 ·Status: TERMINATED ·Phase: PHASE1

Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT01246622 ·Status: COMPLETED ·Phase: PHASE1

Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

NCT03541369 ·Status: TERMINATED ·Phase: PHASE1

Expanded Access to Ziftomenib

NCT05738538 ·Status: AVAILABLE

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

NCT06146257 ·Status: RECRUITING ·Phase: PHASE1

Study of AMV564 in Patients With AML

NCT03144245 ·Status: COMPLETED ·Phase: PHASE1

A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia

NCT01773408 ·Status: COMPLETED ·Phase: PHASE1

High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML

NCT02768792 ·Status: COMPLETED ·Phase: PHASE2

Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT00669318 ·Status: COMPLETED ·Phase: PHASE2

A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia

NCT05712278 ·Status: TERMINATED ·Phase: PHASE1

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)

NCT02610062 ·Status: TERMINATED ·Phase: PHASE1

Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia

NCT01380756 ·Status: COMPLETED ·Phase: PHASE1

Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)

NCT01279473 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

CART123 + Ruxolitinib in Relapsed/Refractory AML

NCT06768476 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

NCT06533761 ·Status: RECRUITING ·Phase: PHASE1

A Safety and Efficacy Study of Eltrombopag in Subjects With AML

NCT01890746 ·Status: COMPLETED ·Phase: PHASE2

Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia

NCT04789655 ·Status: TERMINATED ·Phase: PHASE1

Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia

NCT06769490 ·Status: RECRUITING ·Phase: PHASE1